JAZZ Jazz Pharmaceuticals PLC
Company Analysis
Latest News
🔴 Jazz Pharmaceuticals is trading at 4.7% down as oil prices and Treasury yields rise
Jazz Pharmaceuticals is trading 4.7% lower at $220.37 amid broader market and healthcare-sector pressure, with no clear company-specific announcement...
Jazz Pharma Refinances $1.895 Billion Term Loan, Extending Maturity to 2033
Jazz Pharmaceuticals has amended its credit agreement to refinance its outstanding $1.895 billion Tranche B-2 Dollar Term Loans. This transaction establishes a...
🔴 Jazz Pharmaceuticals is trading 26% down in after-hours trading
Jazz Pharmaceuticals is trading 25.78% down at $178.55 after-hours on September 22, 2026, with the catalyst unclear. - The price compares with a...
Jazz Pharmaceuticals Completes $820M Acquisition of Actio Biosciences
Jazz Pharmaceuticals announced it has successfully completed the acquisition of the privately-held Actio Biosciences for an $820 million upfront payment. The...
CalSTRS Increases Jazz Pharmaceuticals Stake by 24,000% to $3.8 Billion
The California State Teachers Retirement System (CalSTRS) increased its holdings in Jazz Pharmaceuticals by 24,585.6% during the second quarter. A new filing...
Jazz Pharmaceuticals Ziihera Hits Survival Goal, Eyes $5 Billion Peak Sales
Jazz Pharmaceuticals reported positive results from the second interim analysis of its HERIZON-GEA-01 Phase 3 trial for Ziihera (zanidatamab). The study...
JAZZ Completes $1.25 Billion Exchangeable Senior Notes Offering and Share Repurchase
Jazz Pharmaceuticals' subsidiary, Jazz Investments I Limited, has completed a private offering of $1.25 billion in 1.875% exchangeable senior notes due 2032....
Jazz Pharmaceuticals Gains FDA Approval for Ziihera Regimens in First-Line Stomach Cancer
Jazz Pharmaceuticals announced on August 25, 2026, that the U.S. Food and Drug Administration (FDA) has approved two Ziihera® (zanidatamab-hrii) treatment...
Jazz Pharmaceuticals Secures FDA Approval for Ziihera, Eyes $1.5 Billion Peak Sales
Jazz Pharmaceuticals received FDA approval on August 25, 2026, for the expanded use of Ziihera (zanidatamab-hrii). The approval covers first-line treatment for...